GlobeNewswire

China Unicom Teams with Cisco to Enable Cloud + Network Synergy with Segment Routing

Dela

BEIJING, April 17, 2018 (GLOBE NEWSWIRE) -- Recently, China United Network Communications Group Co., Ltd. (China Unicom) officially announced seven new products: Cloud Network Connection, Cloud Networking, Cloud VPV, Cloud Broadband, Unicom Cloud Shield, Intelligent Boutique Video Network, and Boutique Financial Network. China Unicom has achieved a major milestone in pursuing network transformation based on Industrial Internet and has become one of the leading service providers in building "cloud + network" synergy.

Cisco has been collaborating with China Unicom for the past two years, to transform the existing traditional nationwide MPLS VPN network into Industrial Internet with the "cloud + network" synergy based on Segment Routing. This project marks a series of firsts:

  • China's first Segment Routing deployment in a service provider's backbone network;
  • the first case of interconnecting equipment from multiple vendors supporting Segment Routing;  
  • the first case of achieving high availability (HA) with controllers from multiple vendors       

Industrial Internet is a concept derived from Consumer Internet. It refers to the practice of traditional industries leveraging the advantage of big data, cloud computing, smart devices and networks to increase internal efficiency and the ability to provide service for external customers. It is one of the most important ways for traditional industries to realize transformation and upgrade through "Internet+".

China Unicom sharply discovered the tremendous opportunity of Industrial Internet and worked on it as a corporate strategy to build China's first on-demand network that provides network routes with minimal latency for customers, supporting minute-level service launch. However, China Unicom's nationwide MPLS VPN backbone network covers 300 cities with more than 1200 devices, and once it is connected with the IP RAN/SPDC metro network in the future, there will be tens of thousands of devices involved. In addition, "cloud + network" integration requires the ability to provide traffic engineering service for each tenant and each application. This presents an unprecedented challenge to network scalability. None of these issues can be solved by traditional RSVP-TE.               

Segment Routing inherent benefits of network simplification, massive scalability and cross-domain operations support perfectly fit with China Unicom's needs. Interoperability between vendors' devices and controllers was a mandatory requirement.

Cisco used the ASR 9000 router series as the Provider Edge router (PE router), and went beyond traditional third-party equipment (using the static Segment Routing solution) to realize the connection of SRTE. As part of the overall solution, Cisco provided its Network Services Orchestrator (NSO) and WAN Automation Engine (WAE), participated in activities such as business modeling, equipment configuration, topology information collection and route calculation for Cisco and third-party equipment, and successfully delivered a multi-vendor Segment Routing solution.

Cisco also worked with China Unicom to drive and achieve high availability (HA) with multiple vendors' SDN controllers. The system can monitor the condition of the master controller. When the master controller fails, the backup controller from a different vendor can smoothly take over all the business models, business examples, as well as configuration and route information, so as to complete the switching. This innovation is of utmost importance for upcoming 5G/large-scale SDN deployment.

Cisco's Advanced Services teams played a major role in the implementation phase of the project. To align with China Unicom's business strategy, Cisco did some "joint development" and customized development through a "three-step" strategy - consulting, implementation, and optimization. Cisco's solution support team acted as the single Point of Contact (PoC) coordinating with related suppliers to follow up and screen problems, and the time needed to solve problems was reduced by 43%.

Ma Jichun, chief engineer from the digital department of China Unicom's design institute CITC, said: "In the context of the new era, China Unicom strives to work with its partners to build a 'cloud + network' ecosystem by actively adopting SDN, NFV, cloud computing, Ultra-broadband Network and other technologies. There is a broad space for China Unicom and Cisco to engage in close collaboration and work together to develop leading technologies such as Segment Routing and SDN. China Unicom will build future networks with an open attitude, to better meet the new needs of customers."

Jonathan Davidson, Senior Vice President and General Manager of Service Provider Networking at Cisco said: "Cisco and China Unicom have worked to transform its networking model and rebuild an intent-based next-generation network. Our collaboration is Cisco's first Segment Routing deployment case in China involving technology from multiple vendors. We look forward to continuing our joint innovative practices, working together to drive the strategic layout and coordinated development of Industrial Internet."  
    
Cisco is leading the disruption in the industry with its technology innovations in systems; silicon; software and security; and its unrivalled expertise in mass-scale networking, automation, optical, optics, cable access, video, and mobility. Combining these capabilities with Cisco's portfolio of go-to-market security, collaboration, IoT, and professional services, we enable service providers, media and web companies to reduce cost and complexity, help secure their networks, and grow revenue.

Supporting Resources

About China Unicom
China Unicom has branch organizations in 31 Chinese provinces (autonomous regions and municipalities) as well as multiple countries and regions outside of China. It is China's only telecom service provider listed on New York City, Hong Kong and Shanghai at the same time. China Unicom ranked No.241 on the 2017 Fortune Global500 list.

About Cisco
Cisco (NASDAQ:CSCO) is the worldwide technology leader that has been making the Internet work since 1984. Our people, products, and partners help society securely connect and seize tomorrow's digital opportunity today. Discover more at thenetwork.cisco.com and follow us on Twitter at @Cisco.

RSS Feed for Cisco: http://newsroom.cisco.com/rss-feeds

Sara Cicero
Sr. Public Relations Manager 
Cisco 
Service Provider Business
770-236-2181 direct
770-331-0269 cell 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cisco via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum